ProQR Therapeutics (NASDAQ:PRQR) Upgraded to Hold at Wall Street Zen

Wall Street Zen upgraded shares of ProQR Therapeutics (NASDAQ:PRQR) from a strong sell rating to a hold rating in a research report released on Saturday morning.

Several other equities analysts have also weighed in on PRQR. Oppenheimer assumed coverage on shares of ProQR Therapeutics in a research report on Thursday. They issued an “outperform” rating and a $9.00 price objective on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of ProQR Therapeutics in a research note on Thursday, January 22nd. Finally, Citigroup reissued a “market outperform” rating on shares of ProQR Therapeutics in a report on Friday. Six equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, ProQR Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $6.80.

ProQR Therapeutics Price Performance

Shares of PRQR opened at $1.82 on Friday. The company has a market cap of $191.49 million, a PE ratio of -3.96 and a beta of 0.21. The firm has a 50-day moving average of $1.64 and a 200-day moving average of $2.06. ProQR Therapeutics has a one year low of $1.07 and a one year high of $3.10.

ProQR Therapeutics (NASDAQ:PRQR) last released its quarterly earnings data on Thursday, March 12th. The biopharmaceutical company reported ($0.09) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.08) by ($0.01). ProQR Therapeutics had a negative net margin of 255.83% and a negative return on equity of 61.64%. The business had revenue of $5.50 million during the quarter, compared to the consensus estimate of $6.12 million. Analysts expect that ProQR Therapeutics will post -0.31 earnings per share for the current year.

Hedge Funds Weigh In On ProQR Therapeutics

A number of hedge funds have recently added to or reduced their stakes in PRQR. Osaic Holdings Inc. boosted its stake in shares of ProQR Therapeutics by 59.6% in the 2nd quarter. Osaic Holdings Inc. now owns 12,050 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 4,500 shares in the last quarter. Guggenheim Capital LLC acquired a new position in ProQR Therapeutics during the 4th quarter worth approximately $35,000. Moody Lynn & Lieberson LLC bought a new position in ProQR Therapeutics in the 4th quarter valued at approximately $50,000. Invesco Ltd. bought a new position in ProQR Therapeutics in the 4th quarter valued at approximately $51,000. Finally, Fifth Third Bancorp acquired a new stake in ProQR Therapeutics in the third quarter valued at approximately $64,000. Institutional investors own 32.65% of the company’s stock.

ProQR Therapeutics Company Profile

ProQR Therapeutics N.V. is a clinical-stage biotechnology company dedicated to developing RNA-based therapies for severe genetic diseases. Utilizing its proprietary Axiomer® RNA editing platform, ProQR aims to correct disease-causing mutations directly at the messenger RNA level. The company’s pipeline features several investigational candidates, including sepofarsen (formerly QR-110) for Leber congenital amaurosis type 10, QR-421a targeting Usher syndrome and certain forms of retinitis pigmentosa, and QR-313 for dystrophic epidermolysis bullosa.

Founded in 2012 and headquartered in Leiden, the Netherlands, ProQR maintains a significant presence in Cambridge, Massachusetts, to support its clinical research and regulatory initiatives.